SAN DIEGO, May 18, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that the Company and its subsidiaries received two prestigious Stevie® Awards in The 19th Annual American Business Awards®, the U.S.A.’s premier business awards program.
Notably, Medical Marijuana, Inc. CEO Dr. Stuart Titus was honored with a Bronze Stevie® Award for Entrepreneur of the Year – Food & Beverage and Medical Marijuana, Inc.’s subsidiary Kannaway® received a Bronze Stevie® Award for Achievement in Management – Consumer Products – Non-Durables.
“Leading Medical Marijuana, Inc.’s talented team for over a decade has been an honor in itself and I am humbled to be recognized by the American Business Awards this year,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “I look forward to continuing to lead this Company of Firsts as we utilize the recent positive momentum in cannabis and hemp legislation.”
The American Business Awards® accepted over 3,800 nominations, a record number, for this year’s awards from large and small, public and private, for-profit and non-profit US-operating businesses. Awards were given out to top-performing companies and executives in a wide range of categories such as leadership, customer service, management, public relations, and product development. They were reviewed in a judging process by more than 250 professionals worldwide, whose average scores determined the winners.
Details about The American Business Awards and the list of 2021 Stevie winners are available at www.StevieAwards.com/ABA.
About Medical Marijuana, Inc.
We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Neuropathix, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company’s flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.
Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To see Medical Marijuana, Inc.’s corporate video, click here.
Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
Investor Relations Contact:
P. (858) 283-4016